The Effect of Oral Feeding of Lactobacillus casei Strain Shirota on Immunoglobulin E Production in Mice

SUMMARYInteraction of macrophages with bacteria is a stimulus for production of cytokines such as IL-10 and IL-12. IL-12 stimulates T cell and natural killer (NK) cell cytotoxicity and interferon-gamma (IFN-g) production. IL-10 opposes the T cell-stimulating action of IL-12, decreases the release of proinflammatory cytokines from macrophages, and stimulates B cells. We have studied the capacity of human intestinal isolates from the three Lactobacillus species dominating on the human gastrointestinal mucosa, L. plantarum, L. rhamnosus and L. paracasei ssp. paracasei, to induce production of IL-10 and IL-12 from human blood mononuclear cells, or monocytes. Whole killed lactobacilli were potent stimulators of IL-12 over a wide range of bacterial concentrations. Lactobacillus paracasei gave the highest levels of IL-12 (1·5 ng/ml in response to 5 × 10 6 bacteria/ml), roughly 10 times more than obtained by stimulation with L. rhamnosus or L. plantarum. Escherichia coli induced on average < 50 pg/ml of IL-12 regardless of the bacterial concentration used. The secretion of free p40 subunit IL-12 followed the same pattern as the secretion of p70 (bioactive IL-12) with regard to the efficiency of different bacteria as stimulators. Escherichia coli was the most efficient trigger of IL-10 production, inducing 0·5 ng/ml IL-10 after stimulation with 5 × 10 6 bacteria/ml. Lactobacillus rhamnosus induced the highest levels of IL-10 among the lactobacilli (0·5 ng/ml) compared with 0·1 ng/ml evoked by L. plantarum or L. paracasei, but 10 times more bacteria were required for optimal stimulation than with E. coli. When neutralizing anti-IL-10 antibodies were added to the cultures, the IL-12-inducing capacity of L. rhamnosus was increased markedly, while that of E. coli remained low. The results show that mucosa-associated lactobacilli can be potent stimulators of IL-12, and thus potentially of cell-mediated immunity, if they pass over the gut epithelial barrier and interact with cells of the gut immune system.

show abstract

“…IL-12 decreases IL-4 production [33]. Accordingly, certain lactobacilli suppress IgE production in vivo and in vitro [34][35][36].…”

Section: Discussionmentioning

confidence: 99%

Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production

Hessle

Hanson

Wold

1999

Clinical and Experimental Immunology

215

145

View full text Add to dashboard Cite

show abstract

“…Some LAB, such as Lactobacillus rhamnosus GG (Goldin et al, 1996), Lactobacillus acidophilus (Goldin and Gorbach, 1977;Lidbeck et al, 1992), Bifidobacterium longum (Reddy and Rivenson, 1993), Lactobacillus casei strain Shirota (Yasutake et al, 2000) and components of LAB (Shiomi et al, 1982) were shown to exert tumor-suppressing effects. For reduction of allergy, Matsuzaki et al (1998) reported that oral feeding of Lactobacillus casei strain Shirota effectively inhibited Immunoglobulin(Ig)E production both in vivo and in vitro. Besides stimulation of antibody production (Alvarez-Olmos and Oberhelman, 2001) and macrophage activity (Schiffrin et al, 1995), functional effects like inhibition of inflammation (Hart et al, 2003;Chapat et al, 2004), and autoimmune disorders (Gill and Guarner, 2004) were observed.…”

Section: Introductionmentioning

confidence: 99%

Physiological Characteristics and Immunomodulating Activity by Lactobacillus paracasei subsp. paracasei BFI46 Isolated from New-Born Infant Feces

Lim¹,

Kim²,

Cho³

et al. 2010

Korean Journal for Food Science of Animal Resources

View full text Add to dashboard Cite

In order to develop a new starter for fermented milk, Lactobacillus paracasei subsp. paracasei BFI46 (BFI46) obtained from new-born infant feces was investigated for physiological characteristics. Good immunomodulating activity was evident compared with commercial lactic acid bacteria starter cultures. The optimum growth temperature of BFI46 was 40 o C with 12 h required to reach pH 4.3. Testing with 13 different antibiotics revealed greatest sensitivity of BFI46 to penicillin-G and chloramphenicol, and heightened resistance to neomycin, kanamycin and polymyxin. BFI46 displayed higher esterase activities compared to 18 other enzymes, was comparatively tolerant to bile juice and able to survive at pH 2 for 3 h, and displayed high resistance against Escherichia coli and Salmonella Typhimurium with a survival rate of 57.14% and 96.36%, respectively. The results indicate that BFI46 could be an excellent starter culture for fermented milk with high level of immunomodulating activity.

show abstract

“…Y-L Ye et al 456 specific lactic acid bacteria (LAB) strain Lactobacillus casei strain Shirota was orally administered 102 or injected 103 together with the particular allergen. In the murine model of birch pollen allergy, Repa et al demonstrated that intranasal co-application of Lactococcus lactis and L. plantarum strains with the recombinant Bet v 1 protein, before and after sensitization with the allergen, resulted in a shift from Th2 to Th1 responses characterized by a marked reduction in the IgE/IgG2a ratio and increased IFN-c production.…”

Section: Strategies Of Mucosal Immunotherapy For Allergic Diseasesmentioning

confidence: 99%

Strategies of mucosal immunotherapy for allergic diseases

Chuang

Chiang

2011

Cell Mol Immunol

View full text Add to dashboard Cite

Incidences of allergic disease have recently increased worldwide. Allergen-specific immunotherapy (SIT) has long been a controversial treatment for allergic diseases. Although beneficial effects on clinically relevant outcomes have been demonstrated in clinical trials by subcutaneous immunotherapy (SCIT), there remains a risk of severe and sometimes fatal anaphylaxis. Mucosal immunotherapy is one advantageous choice because of its non-injection routes of administration and lower side-effect profile. This study reviews recent progress in mucosal immunotherapy for allergic diseases. Administration routes, antigen quality and quantity, and adjuvants used are major considerations in this field. Also, direct uses of unique probiotics, or specific cytokines, have been discussed. Furthermore, some researchers have reported new therapeutic ideas that combine two or more strategies. The most important strategy for development of mucosal therapies for allergic diseases is the improvement of antigen formulation, which includes continuous searching for efficient adjuvants, collecting more information about dominant T-cell epitopes of allergens, and having the proper combination of each. In clinics, when compared to other mucosal routes, sublingual immunotherapy (SLIT) is a preferred choice for therapeutic administration, although local and systemic side effects have been reported. Additionally, not every allergen has the same beneficial effect. Further studies are needed to determine the benefits of mucosal immunotherapy for different allergic diseases after comparison of the different administration routes in children and adults. Data collected from large, well-designed, double-blind, placebo-controlled, and randomized trials, with post-treatment follow-up, can provide robust substantiation of current evidence.

show abstract

The Effect of Oral Feeding of Lactobacillus casei Strain Shirota on Immunoglobulin E Production in Mice

Cited by 200 publications

References 16 publications

Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production

Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production

Physiological Characteristics and Immunomodulating Activity by Lactobacillus paracasei subsp. paracasei BFI46 Isolated from New-Born Infant Feces

Strategies of mucosal immunotherapy for allergic diseases

Contact Info

Product

Resources

About